ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 309-316

  Metzger, Ralf ^a   Leichman, Cynthia Gail ^a   Danenberg, Kathleen D ^a   Danenberg, Peter V ^a   Lenz, Heinz Josef ^a   Hayashi, Kazuhiko ^a   Groshen, Susan ^a   Salonga, Dennis ^a   Cohen, Hartley ^a   Laine, Loren ^a   Crookes, Peter ^a   Silberman, Howard ^a   Baranda, Joaquina ^a   Konda, Brahma ^a   Leichman, Lawrence ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GENE PRODUCT; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXCISION REPAIR; FEMALE; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA;

EID: 0031982522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.309     Document Type: Article

References (33)

1. Leichman L, Silberman H, Leichman CG, et al: Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California Pilot Program. J Clin Oncol 10:1933-1942, 1992
2. Horikoshi T, Danenberg KD, Stadbauer THW, et al: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108-116, 1992
3. Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1996
4. Reed E: Platinum analogs, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 390-397
5. Carey RW, Hilgenberg AD, Wilkins EW, et al: Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinoma of the esophagus: Evaluation of the chemotherapy component. J Clin Oncol 4:697-702, 1986
6. Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1690, 1991
7. Sundfor K, Trope CG, Hogberg T, et al: Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 77:2371-2378, 1996
8. Ajani J, Ota D, Jessup M, et al: Resectable gastric cancer: An evaluation of preoperative and postoperative chemotherapy. Cancer 68:1501-1506, 1991
9. Van Houten, B: Nucleotide excision repair in Escherichia coli. Microbiological Reviews 54:18-51, 1990
10. Hoeijmakers JHJ: Nucleotide excision repair, II: From yeast to mammals. Trends Genet 9:211-217, 1993
11. Jeggo PA, Carr AM, and Lehman AR: Cloning human DNA repair genes. Int J Radiat Biol 66:573-577, 1994
12. Van Duin M, de Wit J, Odijk H, et al: Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD 10. Cell 44:913-923, 1986
13. Tomkinson AE, Bardwell AJ, Bardwell L, et al: Yeast DNA repair and recombination proteins Rad 1 and Rad 10 constitute a single-stranded DNA endonuclease. Nature 362:860-862, 1993
14. Roberts JJ, Thomson AJ: The mechanism of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol, 22:71-131, 1979
15. Strandberg MC, Bresnick E, Eastman A: DNA crosslinking induced by 1,2,diaminocyclohexanedicholoroplatinum (II) in murine leukemia L1210 cells in comparison with other platinum analogues. Biochimia et Biophysica Acta: 698:128-133, 1982
16. Erickson LC, Zwelling LA, Ducore JM, et al: Differential cytotoxicity and DNA cross-linking in normal and transformed human fibroblasts treated with cis-diaminedichloroplatin (II). Cancer Res 41:2791-2794, 1981
17. Swinnen LJ, Barnes DM, Fisher SG, et al: 1-B-D-arabinofuranosylcytosine and hydroxyurea: Production of cytotoxic synergy with cis-diammninedichloroplatinum (II) and modification of platinum induced DNA interstrand cross-linking. Cancer Res 49:1383-1389, 1989
18. Kraker AJ, Moore CW: Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum (II) resistant P388 murine leukemia cell line. Cancer Lett 38:307-314, 1988
19. Reed E, Ormand P, Bohr VA, et al: Expression of the human DNA repair gene ERCC-1 relates to cisplatin drug resistance in human ovarian cancer cells. Proceedings of the American Association for Cancer Research vol 30, 1989 (abstr 1940)
20. Bramson J, Panasci LC: Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res 53:3237-3240, 1993
21. Zhen W, Link CJ, O'Connor PM, et al: Increased gene specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12:3689-3698, 1992
22. Larminat F, Bohr LA: Role of human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nuc Acid Res 22:3005-3010, 1994
23. Dabolkar M, Bostick-Bruton F, Weber C, et al: ERCC-1 and ERCC-2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992
24. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocynate-phenol-chloroform extraction. Ann Biochem 162:156-159, 1987
25. Crookes P, Leichman CG, Leichman L, et al: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report. Cancer 79:1767-1775, 1997
26. Hamilton TC, Ozols RF, Dabrow MB: Multidrug resistance to alkylating agents and platinum compounds: State of knowledge. Oncology 4:101-106, 1990
27. Hromas RA, North JA, Burnsj CJP: Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett 47:197-201, 1987
28. Eicholtz-Wirth H, Hietal B: The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer 54:239-243, 1986
29. Eastman A, Schuylte N, Sheibani N, et al: Mechanisms of resistance to platinum drugs, in Nicolini M (ed): Platinum and Other Metal Compounds in Cancer Chemotherapy. Boston, MA, Martinus Nijohoff, 1988, pp 178-196
30. Bedford P, Fichtinger-Schepman AMJ, Shellard SA: Differential repair of platinum DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48:3019-3024, 1988
31. Masuda H, Tanaka T, Natsuda H, et al: Increased removal of DNA-bound platinum in human ovarian cancer cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 50:1863-1866, 1990
32. Popoff SC, Beck DJ, Rupp WD: Repair of plasmid DNA damaged in vitro with cis or trans-diamminedichloroplatinum (II). Escherichia coli. Mutat Res 183:129-187, 1987
33. van Duin M, de Wit J, Odijk H, et al: Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO. Cell 44:913-923, 1986